Physician profile
Jonathan Gray Holbrook
NPI 1710307384
$5,946.03
in general payments reported to CMS, 2019-2025
33 companies · $1,043 in 2025
The $1,043 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $516 · 2020: $1,417 · 2021: $318 · 2022: $820 · 2023: $993 · 2024: $839 · 2025: $1,043.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,874.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,874.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,361.37 | 2019-2025 | Watchman Access System, Watchman Flx |
| Pfizer INC. | $915.26 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $538.96 | 2021-2025 | Uptravi, Opsumit, Opsynvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $474.58 | 2021-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $426.87 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $349.60 | 2022-2025 | Camzyos, Eliquis |
| Abbott Laboratories | $256.20 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $243.79 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $226.92 | 2019-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $203.97 | 2021-2023 | Xarelto |
| Amgen INC. | $124.82 | 2022-2025 | Repatha, Repatha |
| Heartflow, INC. | $113.02 | 2023-2025 | Ffrct |
| Novo Nordisk INC | $79.19 | 2023-2025 | Wegovy, Ozempic |
| Lexicon Pharmaceuticals, INC. | $62.59 | 2023-2024 | Inpefa |
| Edwards Lifesciences Corporation | $61.07 | 2023-2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $54.74 | 2022-2025 | Amvuttra, Onpattro |
| Bridgebio Pharma, INC. | $51.72 | 2025 | Attruby |
| Kiniksa Pharmaceuticals, Ltd. | $51.25 | 2023 | Arcalyst |
| United Therapeutics Corporation | $49.43 | 2023-2025 | Tyvaso, Tyvaso |
| Merck Sharp & Dohme LLC | $41.55 | 2021-2022 | |
| Kiniksa Pharmaceuticals International, Plc | $38.27 | 2024 | Arcalyst |
| Daiichi Sankyo INC. | $35.12 | 2024-2025 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $26.46 | 2022-2024 | |
| Altathera Pharmaceuticals LLC | $20.26 | 2023 | Sotalol Hydrochloride |
| Takeda Pharmaceuticals U.S.A., INC. | $18.19 | 2021 | |
| Cardiva Medical, INC. | $17.22 | 2022 | |
| Abiomed | $17.12 | 2021 | |
| Scpharmaceuticals INC. | $16.38 | 2025 | |
| Irhythm Technologies, INC. | $15.93 | 2022 | |
| Biosense Webster, INC. | $14.09 | 2020 | |
| Amarin Pharma, INC. | $13.73 | 2021 | |
| Medtronic, INC. | $13.22 | 2024 | Venaseal |
| Biotronik INC. | $13.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Holbrook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.